Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Common Equity: 2018-2025

Historic Common Equity for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Sep 2025 value amounting to $224.6 million.

  • Arcturus Therapeutics Holdings' Common Equity fell 14.25% to $224.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $224.6 million, marking a year-over-year decrease of 14.25%. This contributed to the annual value of $241.0 million for FY2024, which is 13.48% down from last year.
  • As of Q3 2025, Arcturus Therapeutics Holdings' Common Equity stood at $224.6 million, which was down 2.81% from $231.1 million recorded in Q2 2025.
  • Arcturus Therapeutics Holdings' 5-year Common Equity high stood at $352.6 million for Q1 2021, and its period low was $145.7 million during Q3 2022.
  • Moreover, its 3-year median value for Common Equity was $261.9 million (2024), whereas its average is $262.5 million.
  • As far as peak fluctuations go, Arcturus Therapeutics Holdings' Common Equity soared by 1,976.36% in 2021, and later plummeted by 47.60% in 2022.
  • Arcturus Therapeutics Holdings' Common Equity (Quarterly) stood at $228.2 million in 2021, then climbed by 18.45% to $270.3 million in 2022, then rose by 3.03% to $278.5 million in 2023, then declined by 13.48% to $241.0 million in 2024, then decreased by 14.25% to $224.6 million in 2025.
  • Its Common Equity stands at $224.6 million for Q3 2025, versus $231.1 million for Q2 2025 and $233.8 million for Q1 2025.